Insulin resistance sits at the center of type 2 diabetes research, and tirzepatide — a single molecule engineered to engage two incretin receptors — has become a focal point for investigators asking whether dual-receptor pharmacology changes insulin-sensitivity markers through routes that body-weight change alone cannot explain. This article summarizes what published research models and clinical datasets report, and where the evidence remains preliminary.

Why insulin sensitivity anchors metabolic research

Insulin resistance — a reduced tissue response to circulating insulin — is a recurring variable in type 2 diabetes (T2D) research because it links skeletal muscle, liver, and adipose tissue into a single dysregulated network. When peripheral tissues take up glucose less efficiently, pancreatic beta cells compensate by secreting more insulin; over time, research models describe this compensation faltering, a pattern associated with progressive hyperglycemia. Because of this, investigators studying candidate metabolic agents frequently track two coupled readouts at once: how much insulin the beta cell can release, and how effectively that insulin acts at the periphery.¹⁰

Tirzepatide entered this landscape as a structurally distinct probe. Rather than acting on a single incretin pathway, it was designed to activate two, prompting the research question that organizes this article: in published models and trials, does dual-receptor engagement move insulin-sensitivity markers, and does it do so beyond what weight change would predict? The sections below walk through the reported findings and label their evidence tier honestly.

The dual-incretin design: engaging two receptors

Tirzepatide's defining feature is agonism at both the GIP and GLP-1 receptors within one peptide, in contrast to selective GLP-1 receptor agonists such as dulaglutide or semaglutide that stimulate only the GLP-1 pathway.¹⁰ Detailed pharmacology work characterizes the molecule as an imbalanced and biased agonist: receptor-occupancy modeling suggests greater engagement of the GIP receptor than the GLP-1 receptor, and at the GLP-1 receptor the molecule favors cyclic-AMP signaling over beta-arrestin recruitment, with weaker receptor internalization than native GLP-1. In primary islet preparations, beta-arrestin-1 limited the insulin response to GLP-1 but not to GIP or tirzepatide — a signaling nuance the authors linked to enhanced insulin secretion.⁵ These are mechanistic, largely preclinical observations, but they frame why the two-receptor design is treated as more than the sum of two agonists.

At a systems level, the two incretins are described as complementary. Both GIP and GLP-1 stimulate glucose-dependent insulin secretion from pancreatic beta cells, yet their actions on alpha-cell glucagon differ: GIP is reported to be glucagonotropic during hypoglycemia while GLP-1 is glucagonostatic during hyperglycemia, and GIP additionally acts on adipocytes in ways GLP-1 does not.⁹ In research narratives, this combination is proposed to address several nodes of insulin resistance simultaneously rather than a single one.

Beta-cell function markers in research datasets

Much of the human data on beta-cell function comes from post-hoc analyses of the SURPASS phase 3 program, which relied on fasting biomarkers and homeostatic model assessment (HOMA) indices rather than dynamic clamps. In the SURPASS-1 monotherapy analysis, homeostatic model assessment of beta-cell function (HOMA2-B, computed with C-peptide) increased from baseline by roughly 77–92% across tirzepatide doses versus a negligible change on placebo at 40 weeks.² A frequently circulated “163%” figure does not match the published SURPASS-1 values and is not used here.

Insulin processing markers

Alongside secretion capacity, several analyses tracked how efficiently beta cells convert proinsulin to mature insulin. Both the phase 2b analysis and SURPASS-1 reported reductions in fasting proinsulin and in proinsulin-to-insulin and proinsulin-to-C-peptide ratios with tirzepatide.¹² In research terms, lower ratios are interpreted as improved protein processing and reduced beta-cell secretory stress, though these are inferential markers rather than direct measures of cellular endoplasmic-reticulum stress.

Glucagon suppression

In SURPASS-2, glucose-adjusted glucagon fell substantially with tirzepatide (reported reductions around 53–55% at the higher doses), a change relevant to insulin sensitivity because glucagon drives hepatic glucose output.³ Taken together, these datasets describe a coordinated shift in fasting islet-hormone markers; they do not, on their own, establish durable preservation of beta-cell mass.

Direct insulin-resistance biomarkers

The clearest evidence on insulin sensitivity itself comes from a dedicated phase 1 mechanistic trial that used hyperinsulinemic-euglycemic and other clamp techniques — the reference method in this field. Over 28 weeks, tirzepatide raised the clamp disposition index (which combines insulin secretion and sensitivity) far more than placebo, and the improvement exceeded semaglutide; the analysis attributed this to concurrent gains in the insulin secretion rate and in clamp-measured insulin sensitivity (M-value).⁴ Because this study measured sensitivity directly, it carries more mechanistic weight than the surrogate-index analyses.

Surrogate data align with that direction. In the phase 2b biomarker analysis, tirzepatide 10 mg significantly lowered HOMA2-IR compared with both placebo and dulaglutide, and reduced fasting insulin.¹ SURPASS-2 reported HOMA2-IR reductions of roughly 15.5–24.0% across tirzepatide doses versus about 5.1% with semaglutide 1 mg.³ Markers associated with improved sensitivity — total adiponectin (up about 16–23% in SURPASS-1) and insulin-like growth factor binding proteins IGFBP-1 and IGFBP-2 — also rose with tirzepatide.¹² A separate metabolomic analysis found that branched-chain amino acids and related catabolites — metabolites tied to insulin resistance and future T2D risk — decreased in proportion to HOMA2-IR improvement.⁸

Weight-dependent versus weight-independent effects

A central research question is whether tirzepatide's insulin-sensitivity signal simply tracks its large weight reduction. Two independent analytical approaches suggest weight loss explains only part of the effect. In the phase 2b analysis, multiple linear regression adjusting for age, sex, metformin use, triglycerides, and baseline HbA1c estimated that weight loss accounted for only about 13% and 21% of the HOMA2-IR improvement with tirzepatide 10 mg and 15 mg, respectively.¹

A later formal mediation analysis pooling SURPASS-1, -2, and -5 (2,831 participants) reached a compatible conclusion for glycemic control: roughly 12–27% of the HbA1c difference versus placebo was estimated to be mediated through weight loss as monotherapy, rising to 25–45% on an insulin background, and 54–71% when tirzepatide was compared with semaglutide.⁷ The interpretation offered in these papers is that mechanisms beyond weight reduction — plausibly direct incretin-receptor effects on islet and peripheral tissues — contribute meaningfully to the observed changes. Investigators comparing candidate metabolic peptides sometimes contrast this profile with selective GLP-1 agents such as semaglutide, where weight loss appears to carry a larger share of the glycemic signal.

GIP and adipose tissue: the contested route

The most mechanistically interesting — and least settled — proposed route runs through the GIP receptor in adipose tissue. Reviews describe GIP as directly stimulating lipogenesis and supporting healthy adipocyte function, buffering lipids away from ectopic sites, and increasing adiponectin secretion, which in turn is associated with enhanced muscle and fat glucose uptake.⁶⁹ Paired with the appetite-related actions of GLP-1, this adipose axis is one hypothesis for the weight-independent component described above.

Honesty about tier matters here. Much of the adipose-GIP mechanism derives from rodent and cell models, and a notable tension exists in the human literature: earlier studies reported that people with T2D can be relatively unresponsive to GIP, which makes the human relevance of GIP-receptor agonism an open question that reviewers explicitly flag.⁹ Research groups continue to investigate how a dual agonist might restore or bypass that blunted response. For laboratory teams building comparative panels, next-generation multi-receptor peptides such as retatrutide extend this same line of inquiry to triple-receptor pharmacology.

How the profile compares with selective agonists

The table below summarizes reported directional findings from head-to-head and placebo-controlled analyses. Values are drawn from the cited trials and are surrogate or clamp markers, not clinical endpoints; they describe study populations, not any individual use.

Across these datasets, the recurring pattern is that dual-agonist samples shifted beta-cell and insulin-sensitivity markers further than selective GLP-1 comparators, with independent Japanese SURPASS J-mono analyses reporting similar HOMA2-%S sensitivity gains versus dulaglutide.¹¹ The magnitude varied by trial, background therapy, and whether the marker was a fasting surrogate or a clamp measurement.

Evidence limitations and open questions

Several caveats temper the interpretation. First, most insulin-sensitivity readings outside the phase 1 clamp study are fasting HOMA-based surrogates, which are useful at the group level but are not equivalent to dynamic clamp measurements. Second, many analyses are post-hoc and industry-sponsored, so they are best read as mechanism-generating rather than mechanism-confirming. Third, the adipose-GIP contribution — arguably the most novel proposed route — rests substantially on preclinical models and coexists with human data suggesting blunted GIP responsiveness in T2D.⁶⁹ Reviewers have stated plainly that important mechanistic questions remain unresolved.⁹

What the literature does consistently show is a coordinated set of changes — higher beta-cell function indices, lower insulin-resistance surrogates, suppressed glucagon, and favorable adipokine and metabolite shifts — that are only partly explained by weight change. For research programs, that combination is the reason tirzepatide is a frequently used reference compound when dissecting how incretin pharmacology intersects with insulin sensitivity.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.